The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has requested data from Indian pharma exporters regarding unpaid and delayed payments from foreign buyers. This indicates a potential issue impacting the financial health of Indian pharmaceutical exporters. The positive aspect is that Pharmexcil is proactively addressing the problem to understand its scope. However, the underlying concern is that foreign buyers may be facing financial difficulties or are intentionally delaying payments, which could lead to cash flow problems for Indian companies. This situation could negatively affect the profitability and growth prospects of affected pharmaceutical companies. Investors in the Indian pharmaceutical export sector should monitor this situation closely. Understanding the extent of these payment defaults and the potential impact on the companies’ financial statements is crucial for risk assessment.